Is the continued use of UK plasma sourced cryoprecipitate justified? Response to Makris

By  

BRITISH JOURNAL OF HAEMATOLOGY, Vol. 168, Iss. 6, 2015-03 ,pp. : 910-911

John Wiley & Sons Inc

Access to resources Recommend Favorite

Comment on: Addendum to the British Committee for Standards in Haematology (BCSH): Guidelines for the use of fresh‐frozen plasma, cryoprecipitate and cryosupernatant, 2004 (Br. J Haematol 2004,126,11‐28)

By  

BRITISH JOURNAL OF HAEMATOLOGY, Vol. 180, Iss. 5, 2018-03 ,pp. : 748-749

John Wiley & Sons Inc

Access to resources Recommend Favorite

Addendum to the British Committee for Standards in Haematology (BCSH): guidelines for the use of fresh‐frozen plasma, cryoprecipitate and cryosupernatant, 2004 (Br. J Haematol 2004,126,11‐28) ‐ response to Neisser‐Svae and Heger

By  

BRITISH JOURNAL OF HAEMATOLOGY, Vol. 180, Iss. 5, 2018-03 ,pp. : 749-750

John Wiley & Sons Inc

Access to resources Recommend Favorite

Utilization of frozen plasma, cryoprecipitate, and recombinant factor VIIa for children with hemostatic impairments: An audit of transfusion appropriateness

By  

PEDIATRIC BLOOD & CANCER (ELECTRONIC), Vol. 65, Iss. 4, 2018-04 ,pp. : n/a-n/a

John Wiley & Sons Inc

Access to resources Recommend Favorite

4 Plasma for Therapeutic Use

By  

Transfusion Medicine and Hemotherapy, Vol. 36, Iss. 6, 2009-12 ,pp. : 388-397

Karger

Access to resources Recommend Favorite